Biomarker driven, agentic AI heart failure system of care
that is scalable to all patients in all care settings
to materially improve patient outcomes.
Our differentiation is in capturing an accurate (absolute and direct) biomarker of worsening heart failure with a low cost, simple-to-use, non-invasive device. This approach is highly scalable across diverse healthcare settings and patient populations.
The lung fluid HF biomarker informs our CardioAgent™ therapy sub-agents, guiding diuretic titration and timing of Guideline-Directed Medical Therapy (GDMT) optimization.
Lifewave’s CardioAgent™ system of care engages and empowers patients and their clinicians to proactively manage chronic heart failure in home and remote settings.
Our CardioAgent™ agentic platform automates and distributes clinician workflows to optimize time and reduces clinician burnout.
The LifeWave CardioAgent™ solution will be evidence-based and supportive of value-based care through current economic frameworks and our Software-as-Service subscription business model.
Investigational Device. Limited United States Law to Investigational Use.
CardioConnect™ Cardiogenic Lung Fluid Measurement
- Home Chronic Care and Post-Acute Transitional Care Management
- Worsening Heart Failure Biomarker with Lung Fluid Measurement
- Non-Invasive Direct and Absolute Measure
- 15 sec. Capture over Clothing - BMI Agnostic
- Actionable and Algorithmic Therapeutic Guidance
- Supports Fluid Stabilization and GDMT Management
Harnessing Agentic AI to Improve Heart Failure Patient Outcomes
Among heart failure patients, episodic increases in lung fluid are the number-one factor driving ER visits and hospitalizations. A critical unmet need is identifying these fluid imbalances early, before symptoms, and titrating medication to avert feelings of sickness and hospitalization. Timing the integration of Guideline-Directed Medical Therapy (GDMT) at optimized dosages is challenging and also an unmet need that affects patient well being and their physical function.
LifeWave is building an agentic AI system of care to improve the clinical outcomes of heart failure patients. The system enables personalized care and patient self-management that will avert needless hospitalization and improve healthspan in any setting, especially when cardiology care may not be available.
LifeWave’s CardioAgent™ patient facing agent and its integral therapy sub-agents, reports diuretic and GDMT recommendations to the patient’s clinician for approval and EHR integration to inform a care plan that will stabilize fluids and optimize GDMT. The product’s overarching goal is to improve the life of the patient and reduce the heart failure burden on providers and payors. The system empowers primary care physicians to provide care to stable heart failure patients and the underserved 50% of the 7.5M patients without cardiology care.
Our solution is differentiated by the CardioConnect™ heart failure biomarker sensor, therapy sub-agents, a search sub-agent and an architecture where safety verification is deterministic. Safety-guardrailed search will deliver deterministic, high-trust contextual content, to both patient and clinician. Our CardioAgent™ safety-guardrailed architecture patent portfolio consists of 12 pending applications.
Medical Radar Technology
LifeWave has developed a broad base of intellectual property (ten issued USPTO patents) and expertise in medical radar which uses low-power, Ultra-Wideband (UWB) radio frequency (RF) energy for physiologic assessment. The LifeWave technology meets Federal Communications Commission regulations governing human RF exposure and UWB spectrum for a portable medical device.
Leadership Team
LifeWave Biomedical is led by a team of proven executives across cardiology, digital health, operations, and medical technology. With deep expertise spanning patient care, product innovation, commercialization, and large-scale adoption, the team is united by a mission to transform heart failure management worldwide. A team of proven leaders uniting clinical, operational, and technology expertise to transform heart failure care.
Clinical
Advisors
LifeWave has engaged clinical heart failure leaders to inform our product strategy and clinical outcome studies.
Investors
LifeWave is currently raising secured convertible note and Series A equity financing.
Health System Relationships
LifeWave is collaborating with leading value-based care healthcare systems.